Stock IMNM IMMUNOME, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Immunome, Inc.

Equities

IMNM

US45257U1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
14.26 USD -0.07% Intraday chart for Immunome, Inc. -17.00% +33.27%
02:26pm Immunome, Inc. Appoints Sandra M. Swain to Board of Directors CI
Apr. 15 Guggenheim Starts Immunome With Buy Rating, $35 Price Target MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immunome Appoints Sandra M. Swain to Board of Directors
BU
Immunome, Inc. Appoints Sandra M. Swain to Board of Directors
CI
Guggenheim Starts Immunome With Buy Rating, $35 Price Target
MT
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research Annual Meeting
AQ
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
BU
Wedbush Adjusts Immunome's Price Target to $33 From $27, Maintains Outperform Rating
MT
Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
BU
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
BU
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
AQ
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..
CI
Immunome to Participate in the Leerink Partners Global Biopharma Conference
BU
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
AQ
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
BU
Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
AQ
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
BU
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
AQ
Immunome Closes $230 Million Public Offering
MT
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BU
Immunome Prices Stock Offering at $20 a Share
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMNM Stock
  4. News Immunome, Inc.